SEARCH

SEARCH BY CITATION

References

  • 1
    Arber D,Brunning RD,Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: SwerdlowSH, CampoE, Lee HarrisN, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC); 2008. pp 110123.
  • 2
    Falini, B.,Sportoletti P,Martelli MP. Acute myeloid leukemia with mutated NPM: Diagnosis, prognosis and therapeutic perspectives. Current Opin Oncol 2009; 21: 573581.
  • 3
    Boissel N,Renneville A,Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 36183620.
  • 4
    Chou W-C,Tang J-L,Wu S-J, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 9981004.
  • 5
    Chiu RWK,Murphy MF,Fidler C, et al. Determination of RhD zygosity: Comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach. Clin Chem 2001; 47: 667672.
  • 6
    Gorello P,Cazzaniga G,Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006; 20: 11031108.
  • 7
    Ottone T,Ammatuna E,Lavorgna S, et al. An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn 2008; 10: 212216.
  • 8
    Dvorakova D,Lengerova M,Pospisilova J, et al. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations. Leukemia 2009; 23: 793796.
  • 9
    Barragan E,Pajuelo JC,Ballester S, et al. Minimal residual disease in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression. Clinica Chimica Acta 2008; 395: 120123.
  • 10
    Bacher U,Badbaran A,Fehse B, et al. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37: 135142.
  • 11
    Schnittger S,Kern W,Tschulik C, et al. Minimal residual disease levels assessed by NPM1-mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 22202231.
  • 12
    Suzuki T,Kiyoi H,Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 28542861.
  • 13
    Papadaki C,Dufour A,Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor. Br J Haematol 2008; 144: 517523.
  • 14
    Ommen HB,Schnittger S,Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010; 115: 198205.
  • 15
    Doubek M,Palasek I,Pospisil Z, et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 expression. Exp Hematol 2009; 37: 659672.
  • 16
    Taussig DC,Vargaftig J,Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood 2010; 115: 19761984.